Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liraglutide, RD12014 · 1 trial · 1 indication
Maximum (peak) plasma drug concentration
The area under the plasma concentration curve from 0 to 72 h
| Arm | Type | Description |
|---|---|---|
| Liraglutide injection (RD12014)+ Victoza | EXPERIMENTAL | Subjects receive liraglutide injection(RD12014) in the first cycle and Victoza in the second cycle. |
| Victoza + Liraglutide injection (RD12014) | EXPERIMENTAL | Subjects receive Victoza in the first cycle and liraglutide injection(RD12014) in the second cycle. |
| Name | Type | Description |
|---|---|---|
| Liraglutide injection,RD12014 | DRUG | single dose, s.c. injection |
| Liraglutide injection,Victoza | DRUG | single dose, s.c. injection |
Inclusion Criteria: * 1\. Being willing to participate in the experiment, fully understand and sign the informed consent, fully understand and able to complete the experiment according to the requirements of the experiment protocol; * 2\. Aged between 18 and 45 years old of healthy male subjects ; ...
Top 20 of 31 competitors
Liraglutide (RD12014) is a small molecule being developed for Type 2 Diabetes. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being studied for its potential use in managing this metabolic condition.
Liraglutide (RD12014) is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM. The company is conducting clinical research on this drug candidate for the treatment of Type 2 Diabetes.
Liraglutide (RD12014) is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its safety and pharmacokinetic profile in early-stage clinical trials.
Liraglutide (RD12014) has one completed Phase 1 clinical trial with the identifier NCT05294536. This study was a pharmacokinetic comparison of the Liraglutide injection (RD12014) versus Victoza in healthy Chinese subjects. The trial enrolled 50 male participants and was conducted in China.
Liraglutide (RD12014) is being studied as a potential alternative to Victoza, a reference product. A clinical trial compared the pharmacokinetics of the RD12014 injection with Victoza in healthy subjects. However, RD12014 is a separate investigational drug candidate developed by Sunshine Biopharma.
The completed Phase 1 trial for Liraglutide (RD12014), NCT05294536, was a controlled, randomized, open-label study. It compared the pharmacokinetics of RD12014 with Victoza in 50 healthy Chinese male subjects aged 18 years and older. The trial was conducted in China and focused on healthy volunteers.